Day thirteen of the open letter from over two hundred scientists urging the Australian Director of Biosecurity to use existing BICON powers to require synthetic-nucleic-acid screening on imported genetic material reaches Sunday with the policy answer still on the table and no formal Australian decision yet announced. Day fourteen of U.S. federal silence on AI-enabled bioweapons screening reaches the same Sunday with no agency response, while the National Science Board has been disbanded for sixteen days. The state-capacity divergence between the two answers is the structural fact. [1]

The paper's Friday account of the BICON path against U.S. silence framed the asymmetry. BICON, Australia's Biosecurity Import Conditions system, gives the Director of Biosecurity authority to impose import conditions on twenty thousand-plus product categories, including synthetic nucleic acids, without new legislation. The current condition does not require imports to be sourced from a provider that screens for sequences of concern; the proposed addition is, in the open letter's framing, structurally identical to existing conditions on containment and approved facilities. The UK, the U.S., New Zealand, and the EU have all introduced screening frameworks; Australia is, today, absent from that list. [2]

The U.S. silence is the sharper part of the story. The Twist Bioscience and Microsoft paper on strengthening nucleic-acid screening against generative protein design tools made the technical case in October. The federal response — at NIH, at OSTP, at the Office of Pandemic Preparedness and Response Policy — has been silence. The institutional reading is that an existing-authority answer is available in Canberra and not in Washington, and that the next bio-emergency will price the difference. The next two weeks will tell whether either capital moves first.

-- KENJI NAKAMURA, Tokyo